An Investigation into Improvement of Stability and Efficacy of Intravesical BCG Formulations Using Freeze-Drying Technique Stability and efficacy of intravesical BCG formulations
Trends in Peptide and Protein Sciences,
Vol. 5 (2020),
1 January 2020
,
Page 1-9 (e7)
https://doi.org/10.22037/tpps.v5i.33393
Abstract
Bacillus Calmette–Guérin (BCG) has been used as an intravesical product for the treatment of intermediate and high risk, non-muscle-invasive bladder cancer (NMIBC). Freeze drying technique is highly recommended for product development, however, the microorganism sensitivity to freezing and drying processes is a major chalenge which may lead to poor survival. To overcome this problem, the use of cryoprotectants in intravesical BCG formulation is required. This study was, therefre, planned to design a new formulation, using an attenuated strain of Mycobacterium bovis, which could be produced by freeze drying technique with the aim of prolonging its storage stability and increasing its efficacy as well as the ease of administration. For this purpose, sodium L-glutamate monohydrate (a commonly used stabilizer in domestic BCG suspension formulations) was replaced by lactose monohydrate. New intravesical BCG formulations, both in lyophilized and liquid forms, were eventually evaluated by moisture content assay, viable count assay, bacterial and fungal contamination, safety test and determination of bacterial concentration and O2 consumption. The results were compared with the data obtained for the conventional lyophilized and liquid products. Maximum survival rate was achieved in the presence of 10 % w/v lactose monohydrate for both liquid and lyophilized formulations when stored at less than -10 and 2-8C, respectively. In summary, the freeze-dried formulations developed with lactose monohydrate met the requirements of intravesical BCG in high viability and stability during storage.
HIGHLIGHTS
- Lyophilization technique and lactose monohydrate as a protecting sugar were used to improve the stability, storage conditions, shelf-life and effcicay of intravesical BCG product.
- Maximum survival rate was attained for both liquid and lyophilized lactose-based formulations prepared with 10 %w/v lactose monohydrate and stored at less than -10 and 2-8°C, respectively.
- Freeze-dried products possessed higher stability and efficacy in comparison with corresponding liquid preparations.
- Bacillus Calmette–Guérin
- Cryoprotectant
- Freeze drying
- Intravesical BCG
- Lactose monohydrate
- Mycobacterium bovis
How to Cite
References
Alexandroff, A.B., Jackson, A.M., O’Donnell, M.A. and K. James, (1999). BCG immu-notherapy of bladder cancer: 20 years on.Lancet, 353(9165): 1689–1694.
Franks, F., (1998). Freeze-drying of bioproducts: putting principles into practice.European Journal of Pharmaceutics and Biopharmaceutics, 45: 221–229.
Fuge, O., Vasdev, N., Allchorne, P. and J.S. Green, (2015). Immunotherapy for bladder cancer.Research and Reports in Urology, 7:65-79.
Gandhi, N., Morales, A. and D. Lamm, (2013). Bacillus Calmette-Guerin immuno¬therapy for genitourinary cancer.BJU International, 112(3): 288–297.
Grant, Y., Matejtschuk, P, and P.A. Dalby, (2009). "Rapid optimization of protein freeze‐drying formulations using ultra scale‐down and factorial design of experiment in microplates." Biotechnoligy and Bioengineering, 104(5): 957-964.
R.H. Hatley, (1992). The effective use of differential scanning calorimetry in the optimization of freeze-dried process and formulation.Developments in Biological Standardization, 74:105-119.
Her, L-M. and S.L. Nail, (1994). "Measurement of glass transition temperatures of freeze-concentrated solutes by differential scanning calorimetry." Pharmaceutical Research, 11(1): 54-59.
Hozouri, H., Norouzian, D., Nafissi-Varcheh, N. and R. Aboofazeli, (2014). Challenges to improve the stability and efficacy of an intravesical BCG product.Iranian Journal of Pharmaceutical Research, 13(Supp.), 143-150.
Z. Hubálek, (2003). Protectants used in the cryopreservation of microorganism. Cryobiology, 46:205-229.
Jin, T.H., Nguyen, L., Qu, T. and E. Tsao, (2011). "Improved formulation and lyophilization cycle for rBCG vaccine." Vaccine, 29(29-30): 4848-4852.
Jokisch, J.F., Karl, A. and C. Stief, (2015). Intravesical immunotherapy in non-muscle invasive bladder cancer.Indian Journal of Urology, 31(4): 304-311.
Kasper, J.C. and W. Friess, (2011). "The freezing step in lyophilization: Physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals." European Journal of Pharmaceutics and Biopharmaceutics, 78(2): 248-263.
Kawai, K., Hagiwara, T., Takai, R. and T. Suzuki, (2005). Comparative investigation by two analyticalapproaches of enthalpy relaxation for glassy glucose, sucrose, maltoseand trehalose.Pharmaceutical Research, 22(3):490–5.
Kawai, K., Miyazaki, J., Joraku, A., Nishiyama, H. and H. Akaza, (2013). Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine.Cancer Science, 104(1):22–27.
Liu, T., Viverette, T., Virgin, M., Anderson, M. and P. Dalal, (2005). A study of the impact of freezing on the lyophilization of a concentrated formulation with a high fill depth.Pharmaceutical Development and Technology, 10: 261–272.
Pikal, M.J., Rambhatla, S. and R. Ramot, (2002). The impact of the freezing stage in lyophilization: Effects of the ice nucleation temperature on process design and product quality.American Pharmaceutical Reviews, 5:48–53.
Quaak, S.G., Haanen, J.B., Beijnen, J.H. and B. Nuijen, (2010). Naked plasmid DNA formulation:effect of different disaccharides on stability after lyophilization.AAPS Pharm-SciTech, 11(1):344–50.
Redelman-Sidi, G., Glickman, MS. and B.H. Bochner, (2014). The mechanism of action of BCG therapy for bladder cancer. Nature Reviews Urology, 11(3): 153–162.
Stability Testing of Biotechnological/Biological Products: International Conference on Harmonization, ICH Harmonized Triparties Guideline, Q5C. (2011). Available at https://www.ema.europa.eu/en/ich-q5c-stability-testing-biotechnologicalbiological-products.
Surana, R., Pyne, A. and R. Suryanarayanan, (2004). Effect of preparation method on physical properties of amorphous trehalose.Pharmaceutical Research, 21(7):1167–76.
Sylvester, R.J., van der MEIJDEN A.P, and D.L. Lamm, (2002). Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. the Journal of Urology, 168(5):1964-70.
The British Pharmacopoeia, Vol. 4, London: Medicines and Healthcare Products Regulatory Agency; 2003, BCG vaccine ; p. 2758.
The British Pharmacopoeia, Vol. 4 , London: Medicines and Healthcare Products Regulatory Agency; 2012, BCG for immunotherapy; p. 3770.
World Health Organization (2013, January 13). Recommendations to assure the quality, safety and efficacy of BCG vaccines. Retrieved from https://www.who.int/publications/m/item/trs-979-annex-3-bcg-vax.
- Abstract Viewed: 454 times
- PDF Downloaded: 241 times